Investigating personalized treatment options for Idiopathic Pulmonary Fibrosis using genetic information
Official title: Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
Funded at University of Michigan at Ann Arbor · NIH-11071971 · Data updated 2026-11-12
This study is looking to make treatments for Idiopathic Pulmonary Fibrosis (IPF) better by using genetic information to find out how different people respond to medications like N-Acetylcysteine, so that doctors can provide more personalized care for patients with lung diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | September 20, 2019 |
| Project end | March 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $367,279 |
| NIH project number | 5U24HL145265-06 |
| Project ID | NIH-11071971 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Idiopathic Pulmonary Fibrosis or other interstitial lung diseases who are willing to provide genetic samples and participate in follow-up studies.
✕Less likely to help
Patients with interstitial lung diseases who do not have a genetic predisposition relevant to the study or those who are not willing to participate in genetic testing may not benefit from this research.
What this research studies
This research focuses on improving the diagnosis and treatment of Idiopathic Pulmonary Fibrosis (IPF) by utilizing genetic information to tailor antifibrotic therapies. It aims to identify specific genetic variants that may influence how patients respond to treatments like N-Acetylcysteine (NAC). By collaborating with the Pulmonary Fibrosis Foundation, the study will analyze data from patients with interstitial lung diseases to better understand their conditions and optimize treatment strategies. The research employs advanced statistical methods to ensure robust analysis and interpretation of the data collected.
Why it matters
Potential benefit: If successful, this research could lead to more effective, personalized treatment options for patients with IPF, improving their health outcomes.
How similar studies have gone: Previous research has shown promise in using genetic information to tailor treatments for other conditions, suggesting that this approach could be beneficial for IPF as well.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Spino, Catherine a — University of Michigan at Ann Arbor
- Study coordinator: Spino, Catherine a
Related research
Other NIH-funded projects on the same topics.
-
Investigating personalized treatment options for Idiopathic Pulmonary Fibrosis using genetic information.
This study is looking to help people with Idiopathic Pulmonary Fibrosis (IPF) by using their genetic information to find the best treatments for them, so they can get care that’s more personalized and effective.
-
Investigating the role of the complement pathway in lung diseases
This study is looking at how certain proteins in your body might help us understand the progression of idiopathic pulmonary fibrosis and similar lung diseases, so we can find better treatments tailored just for you.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
How lung cells and their surroundings drive fibrosis in interstitial lung diseases
A study to understand how airway cells, surrounding tissue, and their environment contribute to progressive scarring in interstitial lung diseases.
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.